CA2266659A1 - Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement - Google Patents

Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement Download PDF

Info

Publication number
CA2266659A1
CA2266659A1 CA002266659A CA2266659A CA2266659A1 CA 2266659 A1 CA2266659 A1 CA 2266659A1 CA 002266659 A CA002266659 A CA 002266659A CA 2266659 A CA2266659 A CA 2266659A CA 2266659 A1 CA2266659 A1 CA 2266659A1
Authority
CA
Canada
Prior art keywords
growth factors
mammal
growth factor
fgf
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002266659A
Other languages
English (en)
Inventor
Paule Poulin
Brent Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurospheres Holdings Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2266659A1 publication Critical patent/CA2266659A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Heads (AREA)
  • Chemical Vapour Deposition (AREA)
  • Carbon And Carbon Compounds (AREA)

Abstract

L'invention concerne des procédés de protection des tissus neuraux contre les effets du vieillissement, contre des lésions, des agressions toxiques, des troubles ou maladies neurologiques, ces procédés consistant à administrer des facteurs de croissance aux tissus neuraux d'un mammifère, préalablement à l'apparition d'une lésion ou avant toute manifestation de maladie neurologique ou du vieillissement. Les facteurs de croissances induisent la prolifération de cellules souches neurales pluripotentes et de la descendance de cellules souches neurales ainsi que la production de nouvelles cellules neurales jouant un rôle de support et de protection contre les effets du vieillissement, contre des lésions, des agressions toxiques, des troubles ou maladies neurologiques.
CA002266659A 1996-11-15 1997-11-14 Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement Abandoned CA2266659A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3048596P 1996-11-15 1996-11-15
US60/030,485 1996-11-15
PCT/CA1997/000859 WO1998022127A1 (fr) 1996-11-15 1997-11-14 Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement

Publications (1)

Publication Number Publication Date
CA2266659A1 true CA2266659A1 (fr) 1998-05-28

Family

ID=21854421

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002266659A Abandoned CA2266659A1 (fr) 1996-11-15 1997-11-14 Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement

Country Status (6)

Country Link
EP (1) EP0941109A1 (fr)
JP (1) JP2001504123A (fr)
AU (1) AU5043398A (fr)
CA (1) CA2266659A1 (fr)
NO (1) NO992364L (fr)
WO (1) WO1998022127A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US7790669B1 (en) 1997-08-04 2010-09-07 Neurorepair, Inc. Methods for treating neurological deficits by intrastriatal administration of transforming growth factor alpha (TGF-α)
ATE364315T1 (de) 1999-04-26 2007-07-15 Applied Protein Sciences Llc Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US6677307B2 (en) 1999-08-19 2004-01-13 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
JP2005514926A (ja) 2002-01-14 2005-05-26 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 新規ほ乳類多分化能幹細胞および組成物、その調製方法および投与方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230795T1 (de) * 1993-11-09 2003-01-15 Neurospheres Holdings Ltd In situ modifikation und manipulation von stammzellen des zentralen nervensystems
AU716811B2 (en) * 1994-11-14 2000-03-09 Neurospheres Holdings Ltd Regulation of neural stem cell proliferation
AU2019997A (en) * 1996-03-26 1997-10-17 Neurospheres Holdings Ltd Manipulation of mitotically active cells of the hippocampal region of the brain

Also Published As

Publication number Publication date
NO992364D0 (no) 1999-05-14
EP0941109A1 (fr) 1999-09-15
AU5043398A (en) 1998-06-10
JP2001504123A (ja) 2001-03-27
NO992364L (no) 1999-05-14
WO1998022127A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
Knuckey et al. Differential neuronal and astrocytic expression of transforming growth factor beta isoforms in rat hippocampus following transient forebrain ischemia
Timmer et al. Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms
US8158578B2 (en) Methods for treating neurological deficits
Sapieha et al. Fibroblast growth factor-2 gene delivery stimulates axon growth by adult retinal ganglion cells after acute optic nerve injury
Gravel et al. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons
Sauer et al. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.
Moscoso et al. Synapse-associated expression of an acetylcholine receptor-inducing protein, ARIA/heregulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle
Blesch et al. Axonal responses to cellularly delivered NT-4/5 after spinal cord injury
Vidal-Sanz et al. Death and neuroprotection of retinal ganglion cells after different types of injury
Chandross et al. TNFα inhibits Schwann cell proliferation, connexin46 expression, and gap junctional communication
PT1443955E (pt) Pdgf-bb para o tratamento da doença de parkinson
US8673594B2 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
Ban et al. Intraspinal cord graft of autologous activated Schwann cells efficiently promotes axonal regeneration and functional recovery after rat's spinal cord injury
Johnston et al. Trophic factor secreting kidney cell lines: in vitro characterization and functional effects following transplantation in ischemic rats
Cunningham et al. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease
Rohrer et al. Neurotrophin receptor TrkB activation is not required for the postnatal survival of retinal ganglion cells in vivo
US20030129164A1 (en) Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
Sakata et al. Induction of infarct tolerance by platelet-derived growth factor against temporary focal ischemia
CA2266659A1 (fr) Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement
Kramer et al. P75 nerve growth factor receptor is important for retrograde transport of neurotrophins in adult cholinergic basal forebrain neurons
KR100765496B1 (ko) 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물
WO1998022127A9 (fr) Pretraitement a l'aide de facteurs de croissance afin de proteger le systeme nerveux central contre tout endommagement
Fischer Nerve growth factor reverses spatial memory impairments in aged rats
AU5393001A (en) Pretreatment with growth factors to protect against CNS damage
US20010007657A1 (en) Compositions and methods for manipulating glial progenitor cells and treating neurological deficits

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead